IntelliStem: Universal Vaccine Platform
We have developed a breakthrough technology by gene engineering stem cells to act as a universal vaccine. While COVID-19 has shed light on pandemics, many areas globally are still struggling with endemic pathogens, Our stem cells can be incubated for 9 hours with any pathogen (example, COVID-19, Ebola, Leishmania, lyme...etc) and then the cells become ready to be a vaccine against that pathogen.
Not only the technology protects against mutations and variants but it is less expensive to develop and scale, allowing accessibility to all populations even with limited access.
Covid-19 is not the only pandemic humanity is faces, it was rather a wake up call, we are lucky that it was not a mutation of Ebola that spread across the globe or else humanity would have been doomed. Nevertheless, we are still seeing the challenge of covid and it's variant mutations wrecking havoc.
The biggest challenges facing pandemics are anticipating the next mutations and pathogens and the development costs for every vaccine. leading to "rushed" costly developments with success challenges that yield the vaccines expensive. Also, while COVID-19 got the world's attention because it reached developed countries, unfortunately endemics in Africa and developing countries don't get much attention. Ebola, Malaria, Leishmania are still lost wars and no hope insight to tackle those pathogens.
Gene engineering development allowed us to develop a breakthrough technology by engineering stem cells to be able to identify and target pathogens in a very fast and robust manner.
The engineered cells are prepared and stored, then when needed that are incubated for 9 hours with any pathogen (ex: COVID-19, Leishmania, EBOLA..etc) this allows us to develop an efficacious vaccine against any pathogen within record time. The power of the technology is that no only it is rapid and scalable, but it can target any pathogen even if they mutated or developed variants, why is that? because the cells on their own through they engineered code can identify the best was to target and kill the pathogen.
Health security not only during the times of pandemics but for diseases that are devastating to developed communities that can't afford vaccines, or the attention of big pharma to develop therapies due to lack of interest or money.
- Equip last-mile primary healthcare providers with the necessary tools and knowledge to detect disease outbreaks quickly and respond to them effectively.
Our technology was developed when EBOLA was ravaging through West Africa without a solution insight. due to lack of resources, healthcare providers were not able to identify, validate nor develop a fast deploying solution against pathogens and mutants, which delayed the process and allowed pathogens to spread taking the lives of people with limited access to healthcare.
Our platform not only offers the fastest technology to identify and target a pathogen, but also the most efficacious one against those disease. Also, We are willing to work with WHO to give them rights of the patents to help underprivileged and developed communities.
- Prototype: A venture or organization building and testing its product, service, or business model.
The technology has been tested in many diseases successfully, including leishmania, and of course COVID along with other pathologies and demonstrated a robust successful proof a concept across multiple diseases, the next steps would be deploying a trial in Africa to test the platform where it is needed the most.
- A new technology
A breakthrough technology in the field of cell engineering,never done before, by gene engineering stem cells with a simple elegant code that allows them to transfer into detectives identifying and targeting pathogens ,due to that, we are able to develop a scalable platform that can save lives within record time. the beauty of the technology is that, it is the stem cells themselves through the engineered code that are able to detect and target the best ways to destroy the pathogen.
- Biotechnology / Bioengineering
- Infants
- Children & Adolescents
- Elderly
- Rural
- Peri-Urban
- Urban
- Poor
- Low-Income
- Refugees & Internally Displaced Persons
- 3. Good Health and Well-being
- Canada
- Canada
- United Kingdom
- United States
None yet
-proof of concept in multiple diseases
-manufacturability
-scalability
-reduction of cost
-repeatability and robustness
-bypassing supply chain challenges
-safety and efficacy
- For-profit, including B-Corp or similar models
2 full time
4 part time
We have a track record in successfully developing therapeutics, our team comprises of top scientists in the field of immunology, gene engineering and stem cells.
we make sure to include in our talent search and identification of minorities, women, people of color and LGBTQ+
80% of our team members identify as visible minority
30% of our team members are women.
- Organizations (B2B)
Taking on the challenge and succeeding in developing a universal vaccine goes beyond the developed technology. It requires partnership, collaboration and support. We hope that being part of Solve will give us the platform to advance such an innovative and life saving technology beyond ourselves.
- Human Capital (e.g. sourcing talent, board development, etc.)
- Financial (e.g. improving accounting practices, pitching to investors)
- Public Relations (e.g. branding/marketing strategy, social and global media)
- Product / Service Distribution (e.g. expanding client base)
Human Capital: We are hoping by being part of Solver to attract impressive individuals to join us in this endeavour and provide guidance on how to drive this technology to patients
Financial: Being able to raise the capital to conduct the first in human study
Public Relations and service distribution: Being able to meet with NGOs, Hospitals, Academic institutions, WHO, in order to collaborate and advance the technology to patients
Hospitals, Academic research centre: Collaborate with them on doing the human studies, targeting pathogens that were beyond our experience, for example certain tropical pathogens, conducting the human studies in those centers.
Collaborate with Vaccine development centers to advance the technology
Collaborate with WHO to advance the technology to developing countries
Collaborate with Gatesfoundation to allow the technology to be in the hands of who needs it the most.
- Yes, I wish to apply for this prize
One of the biggest factors in science and biotechnology is using our technology and knowledge for the greater good of humanity and helping other people who are less fortunate.
Therefore, any prize money that we get, we pledge happily to share or forfeit our patents in infectious diseases with low interest such as Malaria, Leishmania...etc, to allow the development of cheap vaccines and therapeutics against such diseases.
- Yes, I wish to apply for this prize
One of the biggest factors in science and biotechnology is using our technology and knowledge for the greater good of humanity and helping other people who are less fortunate.
Therefore, any prize money that we get, we pledge happily to share or forfeit our patents in infectious diseases with low interest such as Malaria, Leishmania...etc, to allow the development of cheap vaccines and therapeutics against such diseases.
- Yes, I wish to apply for this prize
One of the biggest factors in science and biotechnology is using our technology and knowledge for the greater good of humanity and helping other people who are less fortunate.
Therefore, any prize money that we get, we pledge happily to share or forfeit our patents in infectious diseases with low interest such as Malaria, Leishmania...etc, to allow the development of cheap vaccines and therapeutics against such diseases.
- Yes, I wish to apply for this prize
One of the biggest factors in science and biotechnology is using our technology and knowledge for the greater good of humanity and helping other people who are less fortunate.
Therefore, any prize money that we get, we pledge happily to share or forfeit our patents in infectious diseases with low interest such as Malaria, Leishmania...etc, to allow the development of cheap vaccines and therapeutics against such diseases.
- Yes
One of the biggest factors in science and biotechnology is using our technology and knowledge for the greater good of humanity and helping other people who are less fortunate.
Therefore, any prize money that we get, we pledge happily to share or forfeit our patents in infectious diseases with low interest such as Malaria, Leishmania...etc, to allow the development of cheap vaccines and therapeutics against such diseases.